Oxford Immunotec (OXFD) 10.61 $OXFD Oxford Immunotec

New Post Public Reply Private Reply Replies (0) Message Board

Sep 3, 2016 at 11:15 PM

Oxford Immunotec (OXFD) 10.61 $OXFD

Oxford Immunotec Announces Favorable Recommendation by the Magistrate Judge in Patent Infringement Litigation
Globe Newswire - Thu Sep 01, 6:17AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of under-served immune-regulated conditions, today announced that the U.S. Magistrate Judge in the Company's patent infringement lawsuit against Qiagen, Inc., Quest Diagnostics, Inc. and Laboratory Corporation of America Holdings has issued a recommendation denying in substantial part the defendants' motion to dismiss the Company's claims. In issuing his recommendation, the magistrate judge stated, "At this early juncture, the Court concludes that the in vitro aspect of the plaintiff's tuberculosis test is an 'inventive concept' because it improves on prior methods of detecting tuberculosis infection." The magistrate judge's recommendation should now allow the Company to press forward with its case against the three defendants, asserting infringement of its six patents relating to methods for diagnosing TB infection.
DGX: 83.04 (+0.68), OXFD: 10.61 (+0.02)

Oxford Immunotec to Present at the Baird 2016 Global Healthcare Conference
Globe Newswire - Wed Aug 24, 2:15PM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Rick Altieri, Chief Financial Officer, will present at the Baird 2016 Global Healthcare Conference on Wednesday, September 7, 2016, at 2:35 p.m. ET at the New York Palace in New York, NY.
OXFD: 10.61 (+0.02)

Oxford Immunotec Reports Second Quarter 2016 Financial Results
Globe Newswire - Tue Aug 02, 6:00AM CDT
- Second quarter revenue of $19.2 million, increased 34% compared to prior year period
OXFD: 10.61 (+0.02)

Oxford Immunotec Enters into Definitive Agreement to Acquire Imugen
Globe Newswire - Thu Jun 23, 3:05PM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced it has entered into a definitive agreement to acquire substantially all of the assets of Imugen, Inc., a Massachusetts-based clinical laboratory focused on developing and performing specialized testing for tick-borne diseases, for $22.2 million in an all cash transaction expected to close on July 1, 2016.
OXFD: 10.61 (+0.02)

Oxford Immunotec to Present at the Jefferies 2016 Healthcare Conference
Globe Newswire - Fri May 20, 10:45AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 20, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016, at 2:00 p.m. ET at the Grand Hyatt in New York, NY.
OXFD: 10.61 (+0.02)

Oxford Immunotec reports 1Q loss
Automated Insights - Tue May 03, 7:54AM CDT
ABINGDON, Britain (AP) _ Oxford Immunotec Global PLC (OXFD) on Tuesday reported a loss of $7 million in its first quarter.
OXFD: 10.61 (+0.02)

Oxford Immunotec Reports First Quarter 2016 Financial Results
Globe Newswire - Tue May 03, 6:00AM CDT
- First quarter revenue of $17.1 million, increased 24% compared to prior year period
OXFD: 10.61 (+0.02)

Oxford Immunotec Schedules First Quarter 2016 Earnings Release and Conference Call for May 3, 2016
Globe Newswire - Wed Apr 20, 10:08AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that it plans to release first quarter 2016 financial results prior to market open on Tuesday, May 3, 2016. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast.
OXFD: 10.61 (+0.02)

Oxford Immunotec Global appoints Patrick J. Balthrop, Sr. to board
M2 - Tue Feb 02, 3:04AM CST
Diagnostics company Oxford Immunotec Global (NasdaqGM:OXFD) revealed on Monday the election of Patrick J. Balthrop, Sr. to its board of directors.
OXFD: 10.61 (+0.02), LMNX: 21.12 (+0.19)

Patrick J. Balthrop, Sr., Former CEO of Luminex, Joins Oxford Immunotec Board of Directors
Globe Newswire - Mon Feb 01, 4:00PM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the appointment of Patrick J. Balthrop, Sr. to its Board of Directors.
OXFD: 10.61 (+0.02), LMNX: 21.12 (+0.19)

Oxford Immunotec to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
Thomson Reuters ONE - Tue Jan 26, 11:06AM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016, at 1:25 p.m. EST at the Waldorf Astoria in New York, NY.
OXFD: 10.61 (+0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Countries Eye New Investment Paths at CIFIT 2026

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Delhi Pushes Innovation Against Dryland Challenges

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

IASLC Boosts Global Thoracic Cancer Collaboration

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

PathoSearch: A New Era in Pathology With Visual Search

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Nocpix Unveils ACE 2 Thermal Riflescope Lineup

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Silk Road Maritime Extends Its Global Reach in 2026

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

ARTiSTORY's Strategic Advance in Cultural IP Licensing

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...